Name | 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide |
---|---|
Synonyms | 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide |
Description | LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1]. |
---|---|
Related Catalog | |
Target |
p-STAT3 |
In Vitro | LLL12 (0.01-1 μM; 72 h) 在顺铂 (0.5 μM, 2.5 μM) 和紫杉醇 (0.25 μM, 0.5 μM) 作用下均能抑制卵巢癌细胞系的细胞活力[1]。 LLL12 (0.25-1.0μM) 抑制卵巢癌细胞系中 STAT3 磷酸化 (Tyr705)[1]。 Western Blot Analysis[1] Cell Line: A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines Concentration: 0.25, 0.5, and 1 μM for A2780 and OVCAR5; 1, 2.5, and 5 μM for SKOV3 and CAOV-3 Incubation Time: 72 hours Result: Inhibited STAT3 phosphorylation at Tyr705. |
In Vivo | LLL12 (5 mg/kg; 腹腔注射; 每天 1 次, 共 13 天) 在小鼠骨肉瘤细胞和肿瘤生长中表现出强大的生长抑制活性[2]。 Animal Model: Mouse xenografts with SJSA or OS-33 osteosarcoma cells[2] Dosage: 5 mg/kg Administration: Intraperitoneal injection; once daily for 13 days Result: Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice. |
References |
Molecular Formula | C14H9NO5S |
---|---|
Molecular Weight | 303.29000 |
Exact Mass | 303.02000 |
PSA | 122.91000 |
LogP | 2.59610 |